Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI

[at noodls] – Download PDF Study Meets Primary Endpoint Conference Call and Webcast Today at 9:00 A.M. ET to Discuss Results CHICAGO– Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced preliminary, top-line results … more

View todays social media effects on DRTX

View the latest stocks trending across Twitter. Click to view dashboard

See who Durata is hiring next, click here to view